There is little evidence available to demonstrate that inhaled short acting β2-agonists provide an ergogenic effect. However, the majority of research in this area has focused on acute doses of inhaled β2-agonists. At present there are no investigations examining the chronic use of short acting β2-agonist use during training. Ten healthy well-trained males (mean ± SD; age 20.4 ±2.1 years; height 178.1 ±8.8 cm; weight 71.2 ±11.3 kg) who had no history of asthma and presented with a negative indirect airway challenge, volunteered to participate in the study. Athletes were randomly assigned to one of two groups in a randomised double blind design; either placebo or 1600μg salbutamol (400μg (4×100μg inhalations) at 08:00h, 12:00h, 16:00h and 20:00h every day for 6 weeks). Baseline tests consisted of a VO2 peak assessment and a 3km time-trial. Strength assessments consisted of isokinetic dynamometry assessment for peak torque during maximal knee extension and flexion at slow (60°s-1) and fast (240°s-1) contracting speeds, alongside one repetition maximum (1RM) lifts for bench press and leg press, power was assessed via a vertical jump test. Subjects then underwent a 6 week training programme, which consisted of two resistance sessions and two endurance sessions per week, whilst inhaling either 1600μg salbutamol per day or placebo. Follow-up assessments for 3 km time-trial, 1RM bench and leg press, vertical jump heights, VO2 peak and isokinetic dynamometry were undertaken following 6 weeks of training. Mixed-model repeated measures ANOVA were used to compare baseline and 6 week assessments of endurance, strength and power between the salbutamol and placebo groups. There was a significant decrease in 3km completion time post training programme (983.5±183.8 vs. 945.6±186 s, p=0.05) with no difference between groups (salbutamol mean change 23.4±16.5 vs. placebo 52.5±37.1 s, p>0.05). There was no significant effect of the training programme on maximal isokinetic strength or jump height (p>0.05), nor was there a difference between groups (p>0.05). There was a significant increase in VO2 peak post-training (52.5±5.4 vs. 57.7±6.6 ml.kg.min-1, p=0.01) with no difference between groups (p>0.05). There was a significant increase in 1RM leg strength post-training (218.3±45.5 vs. 272.8±48.9 kg, p<0.01) with a significant difference between groups (salbutamol mean change 35±24.7 vs. placebo 78.3±55.3 kg, p=0.04). In conclusion there were significant improvements in performance variables post-training, however these improvements were equal in both groups with no additive effect of inhaled salbutamol on any of the performance or physiological variables. The WADA guidelines that permit up to 1600 μg inhaled salbutamol are appropriate as there appears to be no significant performance enhancing effect of taking this dose on a daily basis.